166 related articles for article (PubMed ID: 14557756)
1. Pharmacodynamics, pharmacokinetics, and safety of multiple doses of FTY720 in stable renal transplant patients: a multicenter, randomized, placebo-controlled, phase I study.
Kahan BD; Karlix JL; Ferguson RM; Leichtman AB; Mulgaonkar S; Gonwa TA; Skerjanec A; Schmouder RL; Chodoff L
Transplantation; 2003 Oct; 76(7):1079-84. PubMed ID: 14557756
[TBL] [Abstract][Full Text] [Related]
2. Multiple-dose FTY720: tolerability, pharmacokinetics, and lymphocyte responses in healthy subjects.
Kovarik JM; Schmouder R; Barilla D; Riviere GJ; Wang Y; Hunt T
J Clin Pharmacol; 2004 May; 44(5):532-7. PubMed ID: 15102874
[TBL] [Abstract][Full Text] [Related]
3. FTY720, a novel immunomodulator in de novo kidney transplant patients: pharmacokinetics and exposure-response relationship.
Skerjanec A; Tedesco H; Neumayer HH; Cole E; Budde K; Hsu CH; Schmouder R
J Clin Pharmacol; 2005 Nov; 45(11):1268-78. PubMed ID: 16239360
[TBL] [Abstract][Full Text] [Related]
4. FTY720, a novel immunomodulator: efficacy and safety results from the first phase 2A study in de novo renal transplantation.
Tedesco-Silva H; Mourad G; Kahan BD; Boira JG; Weimar W; Mulgaonkar S; Nashan B; Madsen S; Charpentier B; Pellet P; Vanrenterghem Y
Transplantation; 2004 Jun; 77(12):1826-33. PubMed ID: 15223899
[TBL] [Abstract][Full Text] [Related]
5. FTY720: early clinical experience.
Dragun D; Fritsche L; Boehler T; Peters H; Budde K; Neumayer HH
Transplant Proc; 2004 Mar; 36(2 Suppl):544S-548S. PubMed ID: 15041403
[TBL] [Abstract][Full Text] [Related]
6. Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study.
O'Connor P; Comi G; Montalban X; Antel J; Radue EW; de Vera A; Pohlmann H; Kappos L;
Neurology; 2009 Jan; 72(1):73-9. PubMed ID: 19122034
[TBL] [Abstract][Full Text] [Related]
7. FTY720 and cyclosporine: evaluation for a pharmacokinetic interaction.
Kovarik JM; Schmouder RL; Barilla D; Büche M; Rouilly M; Berthier S; Wang Y; Van Saders C; Mayer T; Gottlieb AB
Ann Pharmacother; 2004; 38(7-8):1153-8. PubMed ID: 15138297
[TBL] [Abstract][Full Text] [Related]
8. First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients.
Budde K; Schmouder RL; Brunkhorst R; Nashan B; Lücker PW; Mayer T; Choudhury S; Skerjanec A; Kraus G; Neumayer HH
J Am Soc Nephrol; 2002 Apr; 13(4):1073-1083. PubMed ID: 11912269
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics, pharmacodynamics, safety, and tolerability of single-dose fingolimod (FTY720) in adolescents with stable renal transplants.
Ettenger R; Schmouder R; Kovarik JM; Bastien MC; Hoyer PF
Pediatr Transplant; 2011 Jun; 15(4):406-13. PubMed ID: 21585629
[TBL] [Abstract][Full Text] [Related]
10. FTY720: placebo-controlled study of the effect on cardiac rate and rhythm in healthy subjects.
Schmouder R; Serra D; Wang Y; Kovarik JM; DiMarco J; Hunt TL; Bastien MC
J Clin Pharmacol; 2006 Aug; 46(8):895-904. PubMed ID: 16855074
[TBL] [Abstract][Full Text] [Related]
11. FTY720 in combination with cyclosporine--an analysis of skin allograft survival and renal function.
Silva FR; Silva LB; Cury PM; Burdmann EA; Bueno V
Int Immunopharmacol; 2006 Dec; 6(13-14):1911-8. PubMed ID: 17161344
[TBL] [Abstract][Full Text] [Related]
12. A new immunosuppressant, FTY720, in canine kidney transplantation: effect of single-drug, induction and combination treatments.
Suzuki T; Jin MB; Shimamura T; Yamashita K; Taniguchi M; Nomura M; Yokota R; Fukai M; Magata S; Horiuchi H; Fujita M; Nagashima K; Furukawa H; Todo S
Transpl Int; 2004 Nov; 17(10):574-84. PubMed ID: 15592714
[TBL] [Abstract][Full Text] [Related]
13. FTY720, an immunosuppressant that alters lymphocyte trafficking, abrogates chronic rejection in combination with cyclosporine A.
Koshiba T; Van Damme B; Rutgeerts O; Waer M; Pirenne J
Transplantation; 2003 Apr; 75(7):945-52. PubMed ID: 12698078
[TBL] [Abstract][Full Text] [Related]
14. Single-dose FTY720 pharmacokinetics, food effect, and pharmacological responses in healthy subjects.
Kovarik JM; Schmouder R; Barilla D; Wang Y; Kraus G
Br J Clin Pharmacol; 2004 May; 57(5):586-91. PubMed ID: 15089811
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results.
Comi G; O'Connor P; Montalban X; Antel J; Radue EW; Karlsson G; Pohlmann H; Aradhye S; Kappos L;
Mult Scler; 2010 Feb; 16(2):197-207. PubMed ID: 20028707
[TBL] [Abstract][Full Text] [Related]
16. Tolerability and steady-state pharmacokinetics of everolimus in maintenance renal transplant patients.
Budde K; Neumayer HH; Lehne G; Winkler M; Hauser IA; Lison A; Fritsche L; Soulillou JP; Fauchald P; Dantal J;
Nephrol Dial Transplant; 2004 Oct; 19(10):2606-14. PubMed ID: 15316094
[TBL] [Abstract][Full Text] [Related]
17. Safety and pharmacokinetics of ascending single doses of sirolimus (Rapamune, rapamycin) in pediatric patients with stable chronic renal failure undergoing dialysis.
Tejani A; Alexander S; Ettenger R; Lerner G; Zimmerman J; Kohaut E; Briscoe DM
Pediatr Transplant; 2004 Apr; 8(2):151-60. PubMed ID: 15049795
[TBL] [Abstract][Full Text] [Related]
18. A randomized, double-blind, placebo-controlled study to determine safety, tolerance, and preliminary pharmacokinetics of ascending single doses of orally administered sirolimus (rapamycin) in stable renal transplant recipients.
Brattström C; Tydén G; Säwe J; Herlenius G; Claesson K; Groth CG
Transplant Proc; 1996 Apr; 28(2):985-6. PubMed ID: 8623489
[No Abstract] [Full Text] [Related]
19. Treatment of chronic allograft nephropathy at late stages using everolimus or FTY720 in combination with cyclosporine.
Roos M; Liu S; Strobl M; Schmaderer C; Baumann M; Heemann U; Lutz J
Transplant Proc; 2008 Dec; 40(10):3731-6. PubMed ID: 19100477
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic/pharmacodynamic relationships of FTY720 in kidney transplant recipients.
Park SI; Felipe CR; Machado PG; Garcia R; Skerjanec A; Schmouder R; Tedesco-Silva H; Medina-Pestana JO
Braz J Med Biol Res; 2005 May; 38(5):683-94. PubMed ID: 15917949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
